Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Elrexfio (elranatamab by Quarter
Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M) ($M)
Pfizer Elrexfio (elranatamab: $89M in Q2 2026, up 4.7% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
“|| Elrexfio | 89 | 85 | 4% | 5% | 30 | 35 | (15%) | 59 | 50 | 17% | 18%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up elrexfio (elranatamab
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — U.S. revenues ($M)30 · Q2 2026
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — International revenues ($M)59 · Q2 2026
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide reported YoY (%)4.0% · Q2 2026
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide operational (constant-currency) YoY (%)5.0% · Q2 2026
Cite this data
StockData. (2026). Pfizer Elrexfio (elranatamab ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/elrexfio-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.